Avycaz Approval and Labeling Restrictions
![](https://i0.wp.com/allphasepharma.com/dir/wp-content/uploads/2015/08/Avycaz-slider.jpg?resize=640%2C180&ssl=1)
On Feb 25, 2015 the combination of ceftazidime/avibactam (Avycaz) was approved by FDA for cUTI and cIAI infections in patients ‘who have limited or no alternative treatment options’. As a QIDP drug, Avycaz received priority review. Its label states that it is Continue reading Avycaz Approval and Labeling Restrictions